1. A pharmaceutical composition containing a phosphate-binding polymer and not containing added metal ions and / or an added source of monovalent anions. 2. The composition according to claim 1, in which the phosphate-binding polymer is a sevelamer carbonate. A composition according to claim 1, which comprises a wet granular phosphate binding polymer. The composition according to claim 1, in which the metal ions are monovalent, divalent or trivalent and selected from the group consisting of sodium, potassium, calcium, magnesium and aluminum, and the added source of monovalent anions is a metal salt with monovalent anions. A composition according to claim 2, which does not contain crystalline cellulose and / or low-substituted hydroxypropyl cellulose. A pharmaceutical composition comprising a wet granular phosphate binding polymer, preferably Sevelamer carbonate, and at least one polyol that has at least one of the following characteristics: a) less than about 0.05% (w / w) of monovalent anions, other than a bicarbonate anion； b) does not contain added metal ions and / or an added source of monovalent anions； c) said composition is a solid dosage form containing not more than about 90% of particles with a particle size not more than about 400 microns, but not less than about 45 microns, and has a decay time of less than 30 minutes； d) does not contain reducing sugars； e) does not contain agents competing with sevelamer for phosphate-binding action； f) the specified composition contains less about 95 wt.% based on the total weight of the composition. 7. TO1. Фармацевтическая композиция, содержащая фосфатсвязывающий полимер и не содержащая добавленных ионов металла и/или добавленного источника одновалентных анионов.2. Композиция по п.1, в которой фосфатсвязывающий полимер представляет собой карбонат севеламера.3. Композиция по п.1, которая содержит гранулированный во влажном состоянии фосфатсвязывающий полимер.4. Композиция по п.1, в которой ионы металлов являются одно
